Prevalence of metabolic obesity in patients with Barrett's Oesophagus and its potential role in carcinogenesis

| Submission date | Recruitment status No longer recruiting | Prospectively registered | | | |
|-------------------------------|--|--|--|--|--|
| 12/07/2011 | | ☐ Protocol | | | |
| Registration date | Overall study status | Statistical analysis plan | | | |
| 05/01/2012 | Completed | [X] Results | | | |
| Last Edited 06/06/2016 | Condition category Digestive System | [] Individual participant data | | | |

Plain English summary of protocol

http://www.cancerresearchuk.org/cancer-help/trials/a-study-looking-obesity-people-barretts-oesophagus

Contact information

Type(s)

Scientific

Contact name

Dr Matthew Banks

Contact details

University College London Hospital 250 Euston Road London United Kingdom NW1 2BU +44 20 7380 9419 matthew.banks@uclh.nhs.uk

Additional identifiers

Protocol serial number

v.2 06/01/2011

Study information

Scientific Title

Prevalence of metabolic obesity in patients with Barrett's Oesophagus and its potential role in carcinogenesis: a single centre non-randomised controlled trial

Study objectives

The aim of this study is to investigate whether there is a connection between obesity and the development of Barrett's Oesophagus.

Ethics approval required

Old ethics approval format

Ethics approval(s)

East Central London Research Ethics Committee, 09/02/2011, ref: 10/H0721/83

Study design

Single centre non-randomised controlled trial

Primary study design

Observational

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Barrett's Oesophagus and metabolic obesity

Interventions

The study will be divided in 2 phases (total duration 12 months):

Phase 1: Recruitment, collection of data, endoscopy (OGD) biopsy and histology, blood tests (duration 8 months).

- 1. Subjects with known Barretts Oesophagus will be recruited from patients booked to have an OGD on a list dedicated to a Barretts oesophagus surveillance programme undertaken at University College Hospital, UK.
- 2. The control group will be recruited from patients booked to have an elective OGD for other gastrointestinal indications (negative at endoscopy for Barretts Oesophagus).

Phase 2: Gata collection and analysis (duration 4 months)

- 1. Data will be entered into a database
- 2. Data analysis

The prevalence of obesity, overweight and metabolic obesity will be determined. Anthropometric measurements and body composition (bioimpedance) and biochemical indices of metabolic syndrome will be measured. In those subjects with Barrett's Oesophagus histological presence of metaplasia/dysplasia will also be assessed.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Prevalence of overweight, obesity, and metabolic obesity in subjects with Barrett's Oesophagus as compared to subjects without Barrett's Oesophagus (standardised for age and sex).

All the measures will be done only once at baseline, when patients attend their endoscopy test as part of their clinical management.

No follow-up is required.

Key secondary outcome(s))

- 1. The characteristics of body composition, metabolic parameters and serum level of adiponectin /leptin in obese, overweight and metabolic obese subjects compared to those of normal weight.
- 2. The prevalence of abdominal obesity (in obese and overweight subjects) and metabolic obesity in subjects with dysplastic Barrett's oesophagus compared to those without dysplasia.

All the measures will be done only once at baseline, when patients attend their endoscopy test as part of their clinical management. No follow-up is required.

Completion date

30/05/2013

Eligibility

Key inclusion criteria

- 1. Able to understand the nature and requirements of the study and to provide written informed consent
- 2. Aged 18 79 years
- 3. Booked to undergo routine oesophagogastroduodenoscopy

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Αll

Key exclusion criteria

- 1. Weight loss of more than 10% in the last year
- 2. Known decompensated liver disease
- 3. Coeliac disease
- 4. Inflammatory bowel disease
- 5. Previous upper gastrointestinal tract surgery

6. Known malignancy or undergoing treatment for previously resected malignancy

7. Inability to provide informed consent

Date of first enrolment

01/05/2011

Date of final enrolment

30/04/2012

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
University College London Hospital

London United Kingdom NW1 2BU

Sponsor information

Organisation

University College London Hospital [UCLH] (UK)

ROR

https://ror.org/02jx3x895

Funder(s)

Funder type

Charity

Funder Name

University College London Hospital (UCLH) Charities - Clinical Research and Development Committee (CRDC) (UK) ref: GCT/2011/MB-Po

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Available on request

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|-------------------------------|-------------------------------|--------------|------------|----------------|-----------------|
| Results article | results | 01/03/2016 | | Yes | No |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |